Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A; Australasian Leukaemia and Lymphoma Group. Hughes TP, et al. Among authors: hertzberg m. Blood. 2008 Nov 15;112(10):3965-73. doi: 10.1182/blood-2008-06-161737. Epub 2008 Sep 3. Blood. 2008. PMID: 18768781 Free article. Clinical Trial.
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7. Blood. 2011. PMID: 21139079 Free article.
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Among authors: hertzberg m. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Among authors: hertzberg m. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP. Branford S, et al. Among authors: hertzberg m. Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20. Blood. 2013. PMID: 23515925 Free article.
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Hertzberg M, Matthews JP, Stone JM, Dubosq MC, Grigg A, Ellis D, Benson W, Browett P, Horvath N, Januszewicz H, Abdi E, Green M, Bonaventura A, Marlton P, Cannell P, Wolf M; ALLG. Hertzberg M, et al. Am J Hematol. 2014 May;89(5):536-41. doi: 10.1002/ajh.23684. Epub 2014 Feb 21. Am J Hematol. 2014. PMID: 24481640 Free article. Clinical Trial.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. Yeung DT, et al. Among authors: hertzberg m. Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17. Blood. 2015. PMID: 25519749 Free PMC article. Clinical Trial.
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Among authors: hertzberg m. Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20. Lancet Haematol. 2015. PMID: 26685769 Clinical Trial.
266 results